astragaloside a has been researched along with Pulmonary Disease, Chronic Obstructive in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, G; Hou, Y; Jia, C; Liu, K; Wang, W; Zhang, M | 1 |
| Chang, C; Leying, Z; Meiqian, Z | 1 |
2 other study(ies) available for astragaloside a and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Astragaloside IV protects against lung injury and pulmonary fibrosis in COPD by targeting GTP-GDP domain of RAS and downregulating the RAS/RAF/FoxO signaling pathway.
Topics: Animals; Guanosine Triphosphate; Lipopolysaccharides; Lung Injury; Mice; Proteomics; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Signal Transduction | 2023 |
Astragaloside IV Inhibits Cigarette Smoke-Induced Pulmonary Inflammation in Mice.
Topics: Animals; Cells, Cultured; Cigarette Smoking; Female; Janus Kinase 3; Lung Injury; Mice; NF-kappa B; Pneumonia; Pulmonary Disease, Chronic Obstructive; Saponins; STAT3 Transcription Factor; Triterpenes | 2018 |